- Home
- NPV vs WHWK Comparison
NPV vs WHWK Comparison
Compare NPV & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPV | WHWK |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.2M | 233.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | NPV | WHWK |
|---|---|---|
| Price | $11.42 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 38.1K | ★ 653.2K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.87 | $1.57 |
| 52 Week High | $11.81 | $5.50 |
Technical Indicators
Market Signals| Indicator | NPV | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 43.85 |
| Support Level | $11.34 | $3.85 |
| Resistance Level | $11.60 | $4.38 |
| Average True Range (ATR) | 0.07 | 0.38 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 20.83 | 20.35 |
Price Performance
Historical ComparisonAbout NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.